+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Tourettes Syndrome Drugs Market 2023-2027

  • PDF Icon

    Report

  • 149 Pages
  • June 2023
  • Region: Global
  • TechNavio
  • ID: 4833478
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The tourettes syndrome drugs market is forecasted to grow by USD 598.85 mn during 2022-2027, accelerating at a CAGR of 6.69% during the forecast period. The report on the tourettes syndrome drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing awareness about Tourette syndrome, increasing cases of Tourette syndrome across the world, and increasing demand for cost-effective treatments.

The tourettes syndrome drugs market is segmented as below:

By Product

  • Antipsychotics
  • Non-antipsychotics

By Distribution Channel

  • Offline
  • Online

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the increasing R and D investments for Tourette syndrome as one of the prime reasons driving the tourettes syndrome drugs market growth during the next few years. Also, rising strategic alliances among vendors and increasing healthcare infrastructure expenditure will lead to sizable demand in the market.

The report on the tourettes syndrome drugs market covers the following areas:

  • Tourettes syndrome drugs market sizing
  • Tourettes syndrome drugs market forecast
  • Tourettes syndrome drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading tourettes syndrome drugs market vendors that include Asarina Pharma AB, AstraZeneca, Bausch Health Co. Inc., Catalyst Pharmaceuticals Inc., Eli Lilly and Co., Emalex Biosciences Inc., H Lundbeck AS, Johnson and Johnson Services Inc., Medtronic Plc, OtsUKa Holdings Co. Ltd., Paragon Biosciences LLC, Questex LLC, Reviva Pharmaceuticals Holdings Inc, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. Also, the tourettes syndrome drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Antipsychotics - Market size and forecast 2018-2023
  • Non-antipsychotics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS
  • Development of novel therapeutics
  • Increasing strategic alliances
  • Growing number of research studies to understand genetic root cause of Tourette’s syndrome

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • H. Lundbeck AS
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Antipsychotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antipsychotics - Year-over-year growth 2019-2023 (%)
Exhibit 22: Non-antipsychotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Non-antipsychotics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: AstraZeneca Plc - Vendor overview
Exhibit 49: AstraZeneca Plc - Business segments
Exhibit 50: AstraZeneca Plc - Organizational developments
Exhibit 51: AstraZeneca Plc - Geographic focus
Exhibit 52: AstraZeneca Plc - Key offerings
Exhibit 53: AstraZeneca Plc - Key customers
Exhibit 54: Boehringer Ingelheim International GmbH - Vendor overview
Exhibit 55: Boehringer Ingelheim International GmbH - Business segments
Exhibit 56: Boehringer Ingelheim International GmbH - Organizational developments
Exhibit 57: Boehringer Ingelheim International GmbH - Geographic focus
Exhibit 58: Boehringer Ingelheim International GmbH - Segment focus
Exhibit 59: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 60: Boehringer Ingelheim International GmbH - Key customers
Exhibit 61: Eli Lilly and Co. - Vendor overview
Exhibit 62: Eli Lilly and Co. - Business segments
Exhibit 63: Eli Lilly and Co. - Organizational developments
Exhibit 64: Eli Lilly and Co. - Geographic focus
Exhibit 65: Eli Lilly and Co. - Segment focus
Exhibit 66: Eli Lilly and Co. - Key offerings
Exhibit 67: Eli Lilly and Co. - Key customers
Exhibit 68: H. Lundbeck AS - Vendor overview
Exhibit 69: H. Lundbeck AS - Business segments
Exhibit 70: H. Lundbeck AS - Organizational developments
Exhibit 71: H. Lundbeck AS - Geographic focus
Exhibit 72: H. Lundbeck AS - Key offerings
Exhibit 73: H. Lundbeck AS - Key customers
Exhibit 74: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 75: Johnson & Johnson Services Inc. - Business segments
Exhibit 76: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 77: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 78: Johnson & Johnson Services Inc. - Segment focus
Exhibit 79: Johnson & Johnson Services Inc. - Key offerings
Exhibit 80: Johnson & Johnson Services Inc. - Key customers
Exhibit 81: Mylan NV - Vendor overview
Exhibit 82: Mylan NV - Product segments
Exhibit 83: Mylan NV - Organizational developments
Exhibit 84: Mylan NV - Geographic focus
Exhibit 85: Mylan NV - Segment focus
Exhibit 86: Mylan NV - Key offerings
Exhibit 87: Mylan NV - Key customers
Exhibit 88: Otsuka Holdings Co. Ltd. - Vendor overview
Exhibit 89: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 90: Otsuka Holdings Co. Ltd. - Organizational developments
Exhibit 91: Otsuka Holdings Co. Ltd. - Geographic focus
Exhibit 92: Otsuka Holdings Co. Ltd. - Segment focus
Exhibit 93: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 94: Otsuka Holdings Co. Ltd. - Key customers
Exhibit 95: Pfizer Inc. - Vendor overview
Exhibit 96: Pfizer Inc. - Business segments
Exhibit 97: Pfizer Inc. - Organizational developments
Exhibit 98: Pfizer Inc. - Geographic focus
Exhibit 99: Pfizer Inc. - Segment focus
Exhibit 100: Pfizer Inc. - Key offerings
Exhibit 101: Pfizer Inc. - Key customers
Exhibit 102: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 103: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 104: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 105: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 106: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 107: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 108: Teva Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 109: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 110: Teva Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 111: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibit 112: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key customers
Exhibit 114: Validation techniques employed for market sizing
Exhibit 115: Definition of market positioning of vendors

Executive Summary

The publisher recognizes the following companies as the key players in the global tourettes syndrome drugs market: Asarina Pharma AB, AstraZeneca, Bausch Health Co. Inc., Catalyst Pharmaceuticals Inc., Eli Lilly and Co., Emalex Biosciences Inc., H Lundbeck AS, Johnson and Johnson Services Inc., Medtronic Plc, OtsUKa Holdings Co. Ltd., Paragon Biosciences LLC, Questex LLC, Reviva Pharmaceuticals Holdings Inc, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing R and D investments for Tourette syndrome.'

According to the report, one of the major drivers for this market is the growing awareness about Tourette syndrome.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Asarina Pharma AB
  • AstraZeneca
  • Bausch Health Co. Inc.
  • Catalyst Pharmaceuticals Inc.
  • Eli Lilly and Co.
  • Emalex Biosciences Inc.
  • H Lundbeck AS
  • Johnson and Johnson Services Inc.
  • Medtronic Plc
  • Otsuka Holdings Co. Ltd.
  • Paragon Biosciences LLC
  • Questex LLC
  • Reviva Pharmaceuticals Holdings Inc
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.